All Trials

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced/metastatic non-squamous NSCLC harboring EGFR exon 19 del or L858R (ECOG 0–1) with measurable disease and radiographic progression after exactly one prior third-generation EGFR TKI (including adjuvant; stable/asymptomatic treated CNS mets allowed) are randomized to telisotuzumab adizutecan (ABBV-400), a c-Met–targeting ADC delivering a cleavable-linker topoisomerase I inhibitor payload, versus investigator’s choice standard-of-care therapy. The study includes two telisotuzumab adizutecan dose levels initially to select the RP3D, then compares RP3D against standard care.

ClinicalTrials.gov ID: NCT07155187

MK-5684-004: A Phase 3, Randomized, Open-label Study of Opevesostat Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (OMAHA-004)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1) with radiographic/clinical progression on ongoing ADT after exactly one prior next-generation hormonal agent (abiraterone or enzalutamide), with prior PARP inhibitor use or ineligibility/refusal and no prior taxane for mCRPC (docetaxel allowed only in hormone-sensitive setting), are randomized to opevesostat (oral CYP11A1 steroidogenesis inhibitor) plus mandated physiologic glucocorticoid/mineralocorticoid replacement vs switching to the alternative NHA (abiraterone/prednisone or enzalutamide), with outcomes assessed in both AR-LBD mutation–positive and –negative disease.

ClinicalTrials.gov ID: NCT06136650

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma on ongoing ADT (ECOG 0–1) who have progressed after 1–2 prior androgen receptor pathway inhibitors and are chemotherapy-naïve for prostate cancer are randomized to docetaxel (with prednisone) versus docetaxel plus pasritamig, an IV KLK2×CD3 bispecific T-cell–redirecting antibody designed to induce T-cell–mediated killing of KLK2-expressing prostate cancer cells. Treatment continues until confirmed radiographic progression or other protocol-defined discontinuation criteria.

ClinicalTrials.gov ID: NCT07225946

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with previously untreated extensive-stage SCLC (ECOG 0–1, measurable disease) without active/symptomatic CNS metastases and without steroid-requiring or active ILD/pneumonitis. Participants are randomized to ABBV-706 (SEZ6-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload) at one of two IV dose levels plus atezolizumab versus standard carboplatin/etoposide plus atezolizumab (optional lurbinectedin per protocol).

ClinicalTrials.gov ID: NCT07155174

A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated extensive-stage small-cell lung cancer (ECOG 0–1, measurable disease; prior curative-intent chemoradiotherapy for limited-stage allowed if ≥6 months since treatment) are randomized to platinum/etoposide plus pumitamig (BNT327; investigational PD-L1/VEGF-A bispecific antibody combining checkpoint blockade with anti-angiogenic activity) versus the standard atezolizumab plus platinum/etoposide, followed by maintenance with the assigned immunotherapy. Patients with combined SCLC histology, prior PD-(L)1/VEGF-targeted therapy, high bleeding/wound-healing risk, or untreated/symptomatic/large CNS metastases/leptomeningeal disease are excluded.

ClinicalTrials.gov ID: NCT06712355

A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with treatment-naïve extensive-stage small cell lung cancer (ECOG 0–1) and measurable disease, allowing prior curative-intent therapy for limited-stage SCLC if completed ≥6 months earlier, and excluding active CNS metastases/leptomeningeal disease and significant bleeding/fistula risk. Patients receive IV PF-08634404/SSGJ-707 (bispecific anti–PD-1/anti-VEGF antibody combining checkpoint inhibition with anti-angiogenic blockade) plus platinum/etoposide with possible maintenance, compared with atezolizumab plus the same chemotherapy backbone.

ClinicalTrials.gov ID: NCT07226999

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent or progressive endometrial carcinoma (excluding neuroendocrine tumors, carcinosarcoma, or endometrial sarcoma) after 1–3 prior systemic lines including platinum-based chemotherapy and a PD-(L)1 inhibitor, with radiographic progression on/after most recent therapy. Randomized to rinatabart sesutecan (FRα-targeting antibody–drug conjugate delivering a topoisomerase I inhibitor payload) IV q3 weeks vs investigator’s choice single-agent paclitaxel or doxorubicin.

ClinicalTrials.gov ID: NCT07166094

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable locally advanced or metastatic CLDN18.2-positive, HER2-negative gastric/GEJ/distal esophageal adenocarcinoma (ECOG 0–1) are enrolled in PD-L1/ICI-eligibility–defined cohorts. Cohort 1 (PD-L1+ and ICI-eligible) tests the CLDN18.2-targeted ADC sonesitatug vedotin (CLDN18.2-directed, MMAE payload) plus capecitabine with rilvegostomig (PD-1/TIGIT bispecific) or with nivolumab versus standard nivolumab + CAPOX/FOLFOX, while Cohort 2 (PD-L1− or ICI-ineligible) compares sonesitatug vedotin + capecitabine versus zolbetuximab + CAPOX/FOLFOX.

ClinicalTrials.gov ID: NCT07431281

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable stage IV microsatellite-stable colorectal adenocarcinoma (measurable disease, ECOG 0–1; excluding MSI-H/dMMR and BRAF V600E) are randomized to first-line FOLFOX plus bevacizumab with either INCA33890 or placebo. INCA33890 is an investigational bispecific antibody targeting PD-1 and TGFβR2 to combine checkpoint blockade with localized inhibition of TGF-β signaling in PD-1–expressing cells.

ClinicalTrials.gov ID: NCT07284849

A Randomized, Multicenter, Open-Label, Phase 2 Study of Givastomig (TJ033721) in Combination With Nivolumab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated CLDN18.2 Positive and PD-1L Positive Locally Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, unresectable locally advanced or metastatic HER2-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma that is CLDN18.2-positive and PD-L1 CPS ≥1 (ECOG 0–1; measurable disease; prior perioperative therapy allowed if completed ≥6 months prior) are randomized to add givastomig (TJ033721), a CLDN18.2×4-1BB/CD137 bispecific antibody providing tumor-localized T-cell costimulation, to nivolumab plus mFOLFOX or CAPOX versus nivolumab plus the same chemotherapy alone. Two IV givastomig dose levels are tested alongside standard nivolumab/oxaliplatin-fluoropyrimidine chemotherapy.

ClinicalTrials.gov ID: NCT07432295